PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib (PIPA)
PIPA: a Phase Ib Study to Assess the Safety, Tolerability and Efficacy of the PI3K Inhibitors, Taselisib (GDC-0032) or Pictilisib (GDC-0941), in Combination with PAlbociclib, with the Subsequent Addition of Fulvestrant in PIK3CA-mutant Breast Cancers
Sponsor: Institute of Cancer Research, United Kingdom
This PHASE1 trial investigates Advanced Solid Tumours and Breast Cancer and is currently completed. Institute of Cancer Research, United Kingdom leads this study, which shows 9 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Oct 2024 — Present [monthly]
Completed PHASE1
Status: Unknown → Completed
-
Sep 2024 — Oct 2024 [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE1
▶ Show 4 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Unknown Status → Active Not Recruiting
-
Jun 2018 — Dec 2019 [monthly]
Unknown Status PHASE1
-
Sep 2017 — Jun 2018 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE1
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institute of Cancer Research, United Kingdom
- Pfizer
- Roche Pharma AG
- Royal Marsden NHS Foundation Trust
For direct contact, visit the study record on ClinicalTrials.gov .